Business Context and Reporting Period
Company: Contineum Therapeutics, Inc. (CTNM)
Filing Type: Form 8-K (Current Report)
Report Date: May 5, 2026
Reporting Period: First Quarter ended March 31, 2026
Context: The Company issued a press release announcing financial results for the quarter. The filing serves to furnish this information to the SEC but explicitly states the content is not "filed" for liability purposes under Section 18 of the Exchange Act.
Key Financial Metrics
The provided Form 8-K text acts as a cover document referencing a press release (Exhibit 99.1) but does not contain specific numerical data. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for this information.
Guidance, Outlook, and Risks
Guidance and Outlook: The filing text does not contain specific forward-looking statements, guidance, or management commentary regarding future performance.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Unusual Items: No unusual items are described in the filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 5, 2026) for actual financial figures, as they are not embedded in the 8-K text.
- Verify the Company's status as an Emerging Growth Company (indicated as "Yes" in the filing) and its implications for financial reporting standards.
- Confirm the trading symbol CTNM on the Nasdaq Global Select Market.
- Note that the financial information in this 8-K is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.